The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

• DOI: 10.1016/j.crwh.2020.e00221
• Publication Date: 2020-05-16T23:34:32Z
• Authors: Jonathon Anderson; Jordan Schauer; Suzanne Bryant; Cornelia R. Graves
• Keywords: Convalescent plasma; RD1-811; Remdesivir; COVID-19; SARS CoV-2; Gynecology and obstetrics; Article; 3. Good health; Coronavirus; 03 medical and health sciences; 0302 clinical medicine; Pregnancy; Obstetrics and Gynaecology; RG1-991; Surgery

Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus Disease 19 (COVID-19). In this case report we summarize the use of convalescent plasma therapy and then remdesivir as a late addition in the treatment of a critically ill obstetric patient with COVID-19. The patient subsequently improved, was extubated 5 days after initiation of remdesivir, was transitioned to room air 24 h later, and discharged at the completion of remdesivir therapy.